Tango Therapeutics
TNGXNASDAQHigh RiskTargets synthetic lethal interactions in genetically defined cancers, using a proprietary discovery platform to identify vulnerabilities in tumor cells with specific mutations.
Reviewed by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
Market cap
Small cap
Cash position
$400M as of Q2 2025
~24 months runway (derived)
Revenue status
pre revenue
Pipeline assets
5 programs
What does Tango Therapeutics do?
Tango Therapeutics is a biotech company that develops cancer drugs for patients with specific genetic mutations. They focus on a concept called synthetic lethality, where they exploit weaknesses in cancer cells that have lost certain genes. Their main drug, TNG462, targets a protein called PRMT5, which becomes essential for cancer cells that have a deletion of the MTAP gene. This deletion occurs in about 10-15% of all cancers, making it a large market. Tango is also developing drugs for other genetic mutations, like STK11 and BRCA. They are in early-stage trials, so there is a lot of risk, but also potential for big rewards if the drugs work. Investors should watch for data readouts in the coming years, which could cause the stock to move significantly.
What to watch
Enrollment updates and early efficacy data from TNG462 trials
Any safety signals or dose-limiting toxicities in ongoing trials
Competitive data from Amgen's AMG 193 and Mirati's MRTX1719
Management commentary on pipeline prioritization and cash runway
Presentations at major oncology conferences like ASCO and ESMO
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| TNG462 | MTAP-deleted solid tumors | Phase 1 | Q4 2025 | ▼ |
| TNG260 | STK11-mutated solid tumors | Phase 1 | H1 2026 | ▼ |
| TNG456 | MTAP-deleted solid tumors including NSCLC and glioma | Phase 1 | 2026 | ▼ |
| TNG908 | MTAP-deleted solid tumors | Phase 1 | Terminated | ▼ |
| TNG348 | BRCA1/2 mutant or HRD+ solid tumors | Phase 1 | Terminated | ▼ |
Investment thesis
Bull case
Tango has a differentiated approach targeting synthetic lethality, with multiple shots on goal. Lead asset TNG462 shows promising early efficacy in MTAP-deleted tumors, a large patient population. The company has a strong cash position to fund operations into 2027. Upcoming data readouts in 2025-2026 could be transformative. Management has deep oncology expertise.
Bear case
Tango has had two pipeline discontinuations (TNG908 and TNG348), raising concerns about execution. The PRMT5 space is becoming crowded, with larger players like Amgen and Mirati. Early-stage data may not translate to registrational trials. The company is pre-revenue and will need to raise capital, potentially diluting shareholders. Competition from checkpoint inhibitors and other targeted therapies could limit market share.
Key upcoming catalysts
Phase 1 data for TNG462 in MTAP-deleted solid tumors
Q4 2025
Unverified — this date has not been checked against a primary source.
Phase 1 data for TNG260 in STK11-mutant NSCLC
H1 2026
Unverified — this date has not been checked against a primary source.
Phase 1 data for TNG456 in brain tumors
2026
Unverified — this date has not been checked against a primary source.
Risk factors
Clinical trial failures or delays in enrollment
Competitive pressure from other PRMT5 inhibitors
Dependence on successful execution of multiple early-stage programs
Need for additional capital to fund operations beyond 2027
Potential safety issues with novel mechanisms
Comparable companies
Financial snapshot
These figures are drafted by our AI pipeline, not read from SEC filings. Confirm anything you would act on against the company's latest 10-Q or 10-K.
Cash
$400M as of Q2 2025
Q2 2025 — 5 quarters ago
Quarterly burn
$50M
Cash runway
~24 months
$400M ÷ $50M per quarter
Revenue
pre revenue
Institutional ownership
80%
Source: company profile text. These figures come from the company profile text, not from a filing we have parsed. Check them against the latest 10-Q before relying on them.
These figures are out of date
The cash position cited here is from Q2 2025, roughly 5 quarters ago. The company has almost certainly reported since. Check its latest filing before using any of this.
Sponsored
Get premium TNGX analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you